Differences in exposure to stimulatory and inhibitory components of the insulin-like growth factor (IGF) system in patients with femoral neck versus trochanteric fracture.
Boonen
S
S
Vanderschueren
D
D
Venken
K
K
Geusens
P
P
Haentjens
P
P
Mohan
S
S
Baylink
D J
DJ
Bouillon
R
R
D000368:Aged; D000369:Aged, 80 and over; D015519:Bone Density / Q000502:physiology; D001861:Bone Regeneration / Q000502:physiology; D015536:Down-Regulation / Q000502:physiology; D005260:Female; D005265:Femoral Neck Fractures / Q000503:physiopathology*; D006620:Hip Fractures / Q000503:physiopathology*; D006801:Humans; D018972:Insulin-Like Growth Factor Binding Protein 3 / Q000097:blood; D018975:Insulin-Like Growth Factor Binding Protein 5 / Q000097:blood; D007334:Insulin-Like Growth Factor I / Q000819:agonists* / Q000037:antagonists & inhibitors* / Q000502:physiology; D007335:Insulin-Like Growth Factor II / Q000819:agonists* / Q000037:antagonists & inhibitors* / Q000502:physiology; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000503:physiopathology; D012016:Reference Values; D012307:Risk Factors
D018972:Insulin-Like Growth Factor Binding Protein 3; D018975:Insulin-Like Growth Factor Binding Protein 5; D007334:Insulin-Like Growth Factor I; D007335:Insulin-Like Growth Factor II